Skip to content
Mersalyl
Mersalyl is a small molecule pharmaceutical. Mersalyl was first approved as Mersalyl-theophylline on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BC: Mercurial diuretics
— C03BC01: Mersalyl
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMERSALYL
INNmersalyl
Description
Mersalyl (Mersal) is an organomercury compound and mercurial diuretic. It is only rarely used as a drug, having been superseded by diuretic medications that do not contain mercury and are therefore less toxic. It features a Hg(II) centre. Mersalyl was originally adapted from calomel (Hg2Cl2), a diuretic discovered by Paracelsus.
Classification
Small molecule
Drug classanti-inflammatory agents (salicylic acid derivatives)
Image (chem structure or protein)MERSALYL
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID486-67-9
RxCUI—
ChEMBL IDCHEMBL1200943
ChEBI ID—
PubChem CID101318324
DrugBankDB09338
UNII ID5X1IO031V8 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,046 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
14 adverse events reported
View more details